Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations

Similar documents
BASIC PHARMACOKINETICS

Pharmacokinetics Overview

Applied Biopharmaceutics & Pharmacokinetics Sixth Edition

PHA5128 Dose Optimization II Case Study I Spring 2013

PHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.

UNIVERSITY OF THE WEST INDIES, ST AUGUSTINE

General Principles of Pharmacology and Toxicology

Basic Concepts of TDM

BIOPHARMACEUTICS and CLINICAL PHARMACY

Understand the physiological determinants of extent and rate of absorption

1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?

Nontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment

Biopharmaceutics Lecture-11 & 12. Pharmacokinetics of oral absorption

Multiple IV Bolus Dose Administration

Biomath M263 Clinical Pharmacology

PHARMACOKINETICS OF DRUG ABSORPTION

Slide 1. Slide 2. Slide 3. Drug Action and Handling. Lesson 2.1. Lesson 2.1. Drug Action and Handling. Drug Action and Handling.

Drug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila

Introduction to Pharmacokinetics (PK) Anson K. Abraham, Ph.D. Associate Principal Scientist, PPDM- QP2 Merck & Co. Inc., West Point, PA 5- June- 2017

Nonlinear Pharmacokinetics

Basic Concepts in Pharmacokinetics. Leon Aarons Manchester Pharmacy School University of Manchester

Winston Spencer Liauw Cancer Care Centre, St George Hospital, Gray Street, Kogarah NSW 2217, Australia

Determination of bioavailability

Use of PBPK in simulating drug concentrations in pediatric populations: Case studies of Midazolam and Gabapentin

CLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE

PHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Interchangeable Drug Products - Additional Criteria

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

One-Compartment Open Model: Intravenous Bolus Administration:

HTPK: Conducting PK modeling and

Rational Dose Prediction. Pharmacology. φαρμακον. What does this mean? pharmakon. Medicine Poison Magic Spell

Volume 1(3) May-June 2013 Page 351

TDM. Measurement techniques used to determine cyclosporine level include:

PHA First Exam. Fall 2004

PHA 4120 Second Exam Key Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

General Principles of Pharmacology and Toxicology

Lippincott Questions Pharmacology

Noncompartmental Analysis (NCA) in PK, PK-based Design

CEDIAMATE Metformin Tablets USP 500 mg

Pharmacokinetics in Drug Development. Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core

Guideline for Bioequivalence Studies of Generic Products

NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES S3A

Clinical Trials A Practical Guide to Design, Analysis, and Reporting

PHARMACOKINETICS SMALL GROUP I:

Pharmacokinetics One- compartment Open Model Lec:2

Pharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches.

Renal Function. 1. Glomerular filtration 2. Active tubular secretion 3. Passive tubular reabsorption 4. Excretion

Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics

WHY... 8/21/2013 LEARNING OUTCOMES PHARMACOKINETICS I. A Absorption. D Distribution DEFINITION ADME AND THERAPEUIC ACTION

Section 5.2: Pharmacokinetic properties

FDB FOOD AND DRUGS BOARD G H A N A GUIDELINES FOR CONDUCTING BIOEQUIVALENCE STUDIES

Define the terms biopharmaceutics and bioavailability.

Chapter Questions. Modern Pharmacology With Clinical Applications. Sixth Edition

Tutorial. & In case studies 1 and 2, we explore intravenous iv. & Then, we move on to extravascular dosing in case

Principles of Toxicokinetics/Toxicodynanics

PHA Final Exam Fall 2006

Pharmacokinetics of Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

PHAR 7633 Chapter 20 Non Compartmental Analysis

Absolute bioavailability and pharmacokinetic studies in early clinical development using microdose and microtracer approaches.

PHA First Exam Fall 2003

Industrial Toxicology

1 Introduction: The Why and How of Drug Bioavailability Research

Pharmacogenetics and Pharmacokinetics

Click to edit Master title style

Mechanisms of Drug Action

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

It the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues.

Sponsor / Company: Sanofi Drug substance: SAR236553/REGN727 (alirocumab)

Metformin: Mechanistic Absorption Modeling and IVIVC Development

Pharmacokinetics of drug infusions

PHA Spring First Exam. 8 Aminoglycosides (5 points)

Pharmacokinetics I. Dr. M.Mothilal Assistant professor

How to measure what happens in pharmacokinetics

Dr. Nele Plock. Dr. N. Plock, March 11, 2008, American Conference on Pharmacometrics

PHARMACOLOGY-1 PHL-313. Ali Alhoshani Office: 2B 84

C OBJECTIVES. Basic Pharmacokinetics LESSON. After completing Lesson 2, you should be able to:

Helmut Schütz. The Global Bioequivalence Harmonisation Initiative. 12 April 2018 [Session II: Necessity of multiple dose studies in BE testing] 1

Dr. M.Mothilal Assistant professor

Received: ; Revised; Accepted: A REVIEW ON BIOAVAILABILITY AND BIOEQUIVALENCE STUDY Shashi Kant*, Bharat Parashar

Pharmacokinetics of strong opioids. Susan Addie Specialist palliative care pharmacist

Development of Canagliflozin: Mechanistic Absorption Modeling During Late-Stage Formulation and Process Optimization

METHODS OF STUDYING BIOAVAILABILITY AND BIOEQUIVALENCE

Noncompartmental Analysis (NCA) in PK, PK-based Design

Pharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne

Chapter 12 DRUG THERAPY 2001 Dennis A. Noe

INTRODUCTION TO PHARMACOKINETICS

Current Approaches and Applications of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters

NONLINEAR PHARMACOKINETICS: INTRODUCTION

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

ACTIVE TRANSPORT OF SALICYLATE BY RAT JEJUNUM

Revised European Guideline on PK and Clinical Evaluation of Modified Release Dosage Forms

Pharmacokinetics. Karim Rafaat

Guidance Document. Comparative Bioavailability Standards: Formulations Used for System Effects

Tamer Barakat. Abdul Aziz ALShamali. Abdul Aziz ALShamali

PHAR 7632 Chapter 16

Using Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop

Pharmacokinetics and bioavailability derived from various body fluids. Saliva samples instead of plasma samples

ICU Volume 11 - Issue 3 - Autumn Series

Transcription:

Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations Rosenbaum, Sara E. ISBN-13: 9780470569061 Table of Contents 1 Introduction to Pharmacokinetics and Pharmacodynamics. 1 Introduction: Drugs and Doses. 2 Introduction to Pharmacodynamics. 2.1 Drug Effects at the Site of Action. 2.2 Agonists, Antagonists and Concentration Response Relationships. 3 Introduction to Pharmacokinetics. 3.1 Plasma Concentration of Drugs. 3.2 Processes in Pharmacokinetics. 4 Dose-Response Relationships. 5 Therapeutic Range. 5.1 Determination of the Therapeutic Range. 6 Summary. 2 Passage of Drug Through Membranes. 2 Structure and Properties of Membranes. 3 Passive Diffusion. 3.1 Transcellular Passive Diffusion. 3.2 Paracellular Passive Diffusion. 4 Carrier Mediated Transport: Transport Proteins. 4.1 Uptake Transporters: SCL Superfamily. 4.2 Efflux Transporters: ABC Superfamily. 4.3 Characteristics of Transporter System. 4.4 Simulation Exercise. 4.5 Clinical Examples of Transporter s Involvement in Drug Response. 3 Drug Absorption. 1 Introduction: Local and Systemic Administration. 2 Common Routes of Systemic Drug Administration. 2.1 Intravascular Direct Systemic Administration. 2.2 Extravascular Parenteral Routes. 2.3 Other Extravascular Routes. 3 Overview of Oral Absorption. 4 The Extent of Absorption. 4.1 Bioavailability Factor (F). 4.2 Individual Bioavailability Factors. 5 Determinants of the Bioavailability Factor. 5.1 Disintegration. 5.2 Dissolution. 5.3 Formulation Excipients. 5.4 Adverse Events within the Gastrointestinal Lumen. 5.5 Transcellular Passive Diffusion. 5.6 Paracellular Passive Diffusion. 5.7 Uptake and Efflux Transporters. 5.8 Presystemic Intestinal Metabolism or Extraction. 5.9 Presystemic Hepatic Metabolism or Extraction. 6 Factors Controlling the Rate of Drug Absorption. 6.1 Dissolution Controlled Absorption. 6.2 Membrane Penetration-Controlled Absorption. 7 Biopharmaceutics Classification System (BCS). 8 Problems. 4 Drug Distribution. 2 Extent Of Distribution. 2.1 Distribution Volumes. 2.2 Tissue Binding and Plasma Protein Binding: Concentrating Effects. 2.3 Assessment of Extent of Distribution: Apparent Volume of Distribution (Vd).

2.4 Plasma Protein Binding. 3 Rate of Distribution. 3.1 Perfusion Controlled Drug Distribution. 3.2 Diffusion Controlled Drug Distribution. 4 Distribution To The Central Nervous System. 5 Problems. 5 Drug Elimination. 1.1 First Order Elimination. 1.2 Determinants of the Elimination Rate Constant and the Half-Life. 2 Clearance. 2.1 Definition and Determinants of Clearance. 2.2 Total Clearance, Renal Clearance and Hepatic Clearance. 2.3 Relationship Between Clearance, Volume of Distribution, Elimination Rate Constant and the Half-Life. 2.4 Primary and Secondary Parameters. 3. Renal Clearance. 3.1 Glomerular Filtration. 3.2 Tubular Secretion. 3.3 Tubular Reabsorption. 3.4 Putting Meaning into the Value of Renal Clearance. 4. Hepatic Clearance. 4. 4.2 Phase I and Phase II Metabolism. 4.3 The Cytochrome P450 Enzyme System. 4.4 Glucuronidation. 4.5 Drug-Drug Interactions. 4.6 Hepatic Drug Transporters. 4.7 Kinetics of Drug Metabolism. 4.8 Hepatic Clearance. 5. Measurement of Clearances. 5.1 Total Body Clearance. 5.2 Renal Clearance. 5.3 Fraction of the Drug Excreted Unchanged. 6 Problems. 6 Compartmental Models. 2 Expressions For Component Parts of the Dose-Plasma Concentration Relationship. 2.1 Dose: Effective Dose. 2.2 Rate of Absorption. 2.3 Rate of Elimination. 2.4 Rate of Distribution. 3 Putting Everything Together: Compartments and Models. 3.1 One Compartment Model. 3.2 Two Compartment Model. 3.3 Three Compartment Model. 4 Examples of Complete Compartment Models. 4.1 Intravenous Injection in a One Compartment Model with First Order Elimination. 4.2 Intravenous Injection in a Two Compartment Model with First Order Elimination. 4.3 First Order Absorption in a Two Compartment Model with First Order Elimination. 5 Application of Compartment Model to Study Metabolite Pharmacokinetics. 6 Selecting and Applying Models. 7 Problems. 7 Pharmacokinetics of an Intravenous Bolus Injection In a One Compartment Model. 2 One Compartment Model. 3 Pharmacokinetic Equations. 3.1 Basic Equation. 3.2 Half-Life. 3.3 Time to Eliminate a Dose. 4 Simulation Exercises. 4.1 Basic Model Characteristics. 4.2 Effect of Dose. 4.3 Effect of Clearance. 4.4 Effect of Volume of Distribution. 5. Application of the Model. 5.1 Predicting Plasma Concentrations. 5.2 Duration of Action. 5.3 Dose to Give a Desired Initial Plasma Concentration. 5.4 Intravenous Loading Dose.

6. Determination of Pharmacokinetic Parameters Experimentally. 6.1 Study Design for Determination of Parameters. 6.2 Pharmacokinetic Analysis. 6.3 Example. 7 Pharmacokinetic Analysis in Clinical Practice. 8 Problems. 8 An Intravenous Bolus Injection in the Two Compartment Model. 2 Tissue and Compartmental Distribution of the Drug. 2.1 Drug Distribution to the Tissues. 2.2 Compartmental Distribution of Drug. 3 The Basic Equation. 3.1 Distribution: A, a and the distribution t 1/2. 3.2 Elimination: B, ß and the beta& t 1/2. 4 Relationship Between the Macro and Micro-Rate Constants. 5 The Primary Pharmacokinetic Parameters. 5. 5.2 Clearance. 5.3 Distribution Clearance. 5.4 Volume of Distribution. 6 Simulation Exercises. 7 Determination of the Pharmacokinetic Parameters. 7.1 Determination of the Intercepts and Macro Rate Constants. 7.2 Determination of the Micro Rate Constants. 7.3 Determination of the Primary Pharmacokinetic Parameters. 7.4 Example. 8 Clinical Application of the Two Compartment Model. 8.1 Measurement of the Elimination half-life in the Post Distribution Phase. 8.2 Determination of the Loading Dose. 8.3 Evaluation of Dose. Monitoring Plasma Concentrations and Patient-Response. 9 Problems. 9 Pharmacokinetics of Extravascular Drug Administration. 2 First Order Absorption in a One Compartment Model. 2.1 Model And Equations. 2.2 Parameter Determination. 2.3 Absorption Lag-Time. 2.4 Flip Flop Model. 2.5 Determinants of Cmax and Tmax. 3 Bioavailability. 3.1 Bioavailability Parameters. 3.2 Absolute Bioavailability. 3.3 Relative Bioavailability. 3.4 Bioequivalence. 4 Simulation Exercises. 5 Problems. 10 Introduction to Non-Compartmental Analysis. 2 Mean Residence Time. 3 Determination of Other Important Pharmacokinetic Parameters. 4 Different Routes of Administration. 5 Application of NCA To Clinical Studies. 5.1 Example Drug-Drug Interaction Study. 11 Pharmacokinetics of the Intravenous Infusion In A One Compartment Model. 2 Model And Equations. 2.1 Basic Equation. 2.2 Application of Basic Equation. 2.3 Simulation Exercise Part 1. 3 Steady State Plasma Concentration. 3.1 Equation For Steady State Plasma Concentrations. 3.2 Application of the Equation. 3.3 Basic Formula Revisited. 3.4 Factors Controlling the Steady State Plasma Concentration. 3.5 Time to Steady State. 3.6 Simulation Exercise Part 2.

4 Loading Dose. 4.1 Loading Dose Equation. 4.2 Example Calculation. 4.3 Simulation Exercise Part 3. 5 Termination of Infusion. 5.1 Equations for Termination Before or After Steady State. 5.2 Simulation Exercise Part 4. 6 Monitoring and Individualizing Therapy. 7 Problems. 12 Multiple Intravenous Bolus Injections In The One Compartment Model. 2 Terms And Symbols Used in Multiple Dosing Equations. 3 Mono-Exponential Decay During A Dosing Interval. 3.1 Calculation Of Dosing Interval To Give Specific Steady State Peaks And Troughs. 4 Basic Equations For Multiple Doses. 4.1 Principle Of Superposition. 4.2 Equations that Apply Before Steady State. 4.3 Application Of Equations: Example. 5 Steady State. 5.1 Steady State Equations. 5.2 Average Plasma Concentration at Steady State. 5.3 Fluctuation. 5.4 Accumulation. 5.5 Time To Reach Steady State. 5.6 Loading Dose. 6 Basic Formula Revisited. 7 Pharmacokinetic-Guided Dosing Regimen Design. 7.1 General Considerations for the Selection of the Dosing Interval. 7.2 Protocols For Pharmacokinetic Guided Dosing Regimens. 8 Simulation Exercises. 9 Problems. 13 Multiple Intermittent Infusions. 2 Steady State Equations for Multiple Intermittent Infusions. 3 Mono-exponential Decay During A Dosing Interval: Determination of Peaks, Toughs and Elimination Half-Life. 3.1 Determination of Half-Life. 3.2 Determination of Peaks and Troughs. 4 Determination of the Volume of Distribution. 5 Individualization of Dosing Regimens. 6 Simulation Exercises. 7 Problems. 14 Multiple Oral Doses. 2 Steady State Equations. 2.1 Time to Peak Steady State Plasma Concentration (TMAX,SS). 2.2 Value of Peak Steady State Plasma Concentration (CMAX,SS). 2.3 Value of Trough Steady State Plasma Concentration (CMIN,SS). 2.4 Average Steady State Plasma Concentration (Cpav,SS). 2.5 Overall Effect of Absorption Parameters on a Steady State Dosing Interval. 3 Equations Used Clinically to Individualize Oral Doses. 4 Simulation Exercises. 15 Nonlinear Pharmacokinetics. 1 Linear Pharmacokinetics. 2 Non-Linear Processes In Absorption, Distribution, Metabolism and Excretion. 3 Pharmacokinetics Of Capacity Limited Metabolism. 3.1 Kinetics of Enzymatic Processes. 3.2 Plasma Concentration-Time Profile. 4 Phenytoin. 4. 4.2 Basic Equation Basic For Steady State. 4.3 Estimation of Doses and Plasma Concentrations. 4.4 Influence of Km and Vmax and Factors Affecting These Parameters. 4.5 Time to Eliminate the Drug. 4.6 Time to Reach Steady State. 4.7 Individualization of Doses of Phenytoin. 5. Problems. 16 Introduction to Pharmacodynamic Models and Integrated Pharmacokinetic- Pharmacodynamics (PK-PD)

Models. 2 Classical Pharmacodynamic Models Based on Receptor Theory. 2.1 Receptor Binding. 2.2 Response-Concentration Models. 3 Empirical Pharmacodynamic Models Used Clinically. 3.1 Sigmoidal Emax and Emax Model. 3.2 Linear Adaptations. 4 Integrated PK-PD Models: Intravenous Bolus Injection in the 1-Compartment Model and the Sigmoidal Emax Model. 4.1 Simulation Exercise. 5 Hysteresis and the Effect Compartment. 5.1 Simulation Exercise. 17 Mechanism Based Integrated Pharmacokinetic-Pharmacodynamic Models. 2 Alternative Models For the Drug-Receptor Interaction: Operational Model of Agonism. 2.1 Simulation Exercise. 3 Physiological Turnover Model and its Characteristics. 3.1 Points of Drug Action. 3.2 System Recovery After Change in Baseline Value. 4 Indirect Effect Models. 4. 4.2 Characteristics of Indirect Effect Drug Responses. 4.3 Characteristics of Indirect Effect Models Illustrated Using Model I. Inhibition of kkin. 4.4 The Other Indirect Models. 5 Transduction and Transit Compartment Models. 5.1 Simulation Exercise. 6 Tolerance Models. 6.1 Counter-Regulatory Force Model. 6.2 Precursor Pool Depletion Model. 7 Irreversible Drug Effects. 7.1 Application of the Turnover Model to Irreversible Drug Action. 7.2 Model For Hematological Toxicity of Anticancer Drugs. 8 Disease Progression Models. 8.1 Generation of Drug Response. 8.2 Drug Interaction With the Disease. 8.3 Disease Progression Models. Appendices. Appendix :1 Review of Exponents and Logarithms. 1 Exponents. 2 Logarithms: Log and Ln. 3 Performing Calculations in the Logarithm Domain. 3.1 Multiplication. 3.2 Division. 3.3 Reciprocals. 3.4 Exponents. 4 Examples of calculations using exponential expressions and logarithms. 5 The Decay Function. 6 The Growth Function. 7 The Decay Function in Pharmacokinetics. 8 Problems. Appendix 2: Rates of Processes. 2 Order of a Rate Process. 3 Zero Order Process. 4 First Order Process. 4.1 Equation For a First Order Process. 4.2 Time For 50% Completion: The Half-Life. 5 Comparison of Zero and First Order Processes. 6 Detailed Example of First Order Decay in Pharmacokinetics. 6.1 Equations and Semi-logarithmic Plots. 6.2 The Half-Life. 6.3 Fraction or Percent Completion of a First Order Process Using First Order Elimination as an Example. 7 Examples of the Application of First Order Kinetics to Pharmacokinetics. Appendix 3: Creation of Excel Worksheets for Pharmacokinetic Analysis. 1 Measurement of AUC and Clearance. 1.1 Trapezoidal Rule. 1.2 Excel Worksheet to Determine AUC0 8 and Clearance.

2 Analysis of Data from an Intravenous Bolus Injection in a One-Compartment Model. 3 Analysis of Data from an Intravenous Bolus Injection in a Two-Compartment Model. 4 Analysis of Oral Data in One Compartment Model. 5 Non-Compartmental Analysis of Oral Data. Appendix 4: Derivation of the Equations For Multiple Intravenous Bolus Injections. 1 Assumptions. 2 Basic Equation for Plasma Concentrations After Multiple Intravenous Bolus Injections. 3 Steady State Equations. Appendix 5: Summary of the Properties of the Fictitious Drugs Used in the Text. Glossary of Common Abbreviations and Symbols.